Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) appointed Dr. Dimitrios Iliopoulos to its Advisory Board on February 24, 2026 to support AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos brings academic, biotech leadership, and AI platform experience, including a Phase 2 AI-derived small molecule program.

News Market Reaction – COSM

-3.42%

5 alerts

-3.42% News Effect

+11.1% Peak Tracked

-2.5% Trough Tracked

-$494K Valuation Impact

$14M Market Cap

1.3x Rel. Volume

On the day this news was published, COSM declined 3.42%, reflecting a moderate negative market reaction. Argus tracked a peak move of +11.1% during that session. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $494K from the company's valuation, bringing the market cap to $14M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Clinical trial phase: Phase 2 Scientific publications: More than 130 articles Citation count: Over 24,000 citations +2 more

5 metrics

Clinical trial phase Phase 2 ATH-063 trial in ulcerative colitis patients

Scientific publications More than 130 articles Peer-reviewed biomedical journals

Citation count Over 24,000 citations Citations of Dr. Iliopoulos’ scientific work

Scientist ranking Top 2% Listed in Stanford University’s top 2% scientists worldwide

Book edition 2nd Edition Biotechnology Valuation & Investing

Market Reality Check

Price: $0.3980 Vol: Volume 429,496 is below t...

low vol

$0.3980 Last Close

Volume Volume 429,496 is below the 755,488 20-day average (relative volume 0.57x). low

Technical Shares at $0.3731 are trading below the $0.65 200-day MA and 71.73% under the 52-week high, while sitting 33.2% above the 52-week low.

Peers on Argus

COSM gained 0.88% while peers were mixed: several declined (e.g., ZYXI -37.34%, ...

COSM gained 0.88% while peers were mixed: several declined (e.g., ZYXI -37.34%, EDAP -3.62%, SNYR -2.78%) and one advanced (YI +2.44%), indicating a stock-specific reaction rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Real estate valuation	Positive	-4.6%	Highlighted real estate fair value exceeding market cap and exploring monetization.
Feb 18	Product distribution	Positive	+9.5%	C-Scrub cleanser added to Superdrug, expanding UK retail and pharmacy reach.
Feb 18	Product distribution	Positive	+9.5%	C-Scrub listing at Tesco, broadening UK visibility and access.
Feb 17	Brand promotion	Positive	-4.8%	Showcased proprietary nutraceutical and wellness brands at Dubai health expo.
Feb 11	Crypto investment	Neutral	-2.2%	Expanded digital assets program with additional Bitcoin purchase and crypto strategy.

Pattern Detected

Recent COSM news often produced mixed or negative price reactions, including selloffs after positive operational updates, with only the UK C-Scrub expansion headlines showing positive alignment.

Recent Company History

In the last weeks, Cosmos Health issued several updates tied to operations and assets. On Feb 11, it expanded its digital assets program with a $500,000 Bitcoin purchase, bringing cryptocurrency investments to $2.5 million, followed by a mild share decline. Subsequent announcements on product exposure at World Health Expo Dubai and C-Scrub’s Tesco and Superdrug listings in the UK drew mixed reactions, despite expanding distribution. A later disclosure of real estate assets with fair value above the then-market cap also saw shares decline. Today’s AI-focused advisory appointment adds a biotechnology and drug-discovery dimension to this narrative.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$200,000,000 registered capacity

An effective Form S-3 shelf filed on Nov 7, 2025 registers up to $200,000,000 of securities, including a prospectus supplement for an at-the-market offering of up to $100,000,000 of common stock through A.G.P., providing flexibility for future capital raises and ATM sales.

Market Pulse Summary

This announcement adds a globally recognized AI and clinical-stage biotech specialist to Cosmos Heal...

Analysis

This announcement adds a globally recognized AI and clinical-stage biotech specialist to Cosmos Health’s advisory board, reinforcing its ambitions in AI-driven drug discovery and therapeutic development. In recent months, the company highlighted crypto treasury moves, product distribution gains, and real estate asset value, with mixed share reactions. Investors may monitor how this appointment supports tangible progress in oncology and autoimmune programs, complements existing initiatives, and interacts with the company’s broader capital structure and growth strategy.

Key Terms

ai-driven drug discovery, clinical-stage, ulcerative colitis, autoimmune diseases, +4 more

8 terms

ai-driven drug discovery technical

"biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage"

AI-driven drug discovery uses advanced computer programs to spot promising drug targets and molecules by analyzing large sets of biological and chemical data, accelerating steps that used to take many years of lab work. Investors care because it can cut research costs, shorten development timelines and raise the odds of finding viable medicines—think of it as using a smart metal detector to find valuable items more efficiently than digging at random—while still carrying scientific and regulatory risk.

clinical-stage medical

"AI software and clinical-stage biotechnology company focused on developing precision"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

ulcerative colitis medical

"ATH-063, an AI-derived small molecule currently being evaluated in a Phase 2 clinical trial in ulcerative colitis patients."

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

autoimmune diseases medical

"precision therapeutics for autoimmune diseases. Athos has developed AthosOmics.AI"

Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.

oncology medical

"strategies that have significantly accelerated drug discovery in oncology and autoimmune"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

metformin medical

"drug repositioning demonstrated that metformin, a widely used anti-diabetic drug,"

A widely used oral medication for lowering blood sugar in people with type 2 diabetes, metformin helps the body use insulin more effectively and reduces how much sugar the liver releases. For investors, metformin matters because it is a high-volume, often-generic drug whose sales, regulatory changes, patent status, new clinical uses, or safety signals can affect pharmaceutical revenues and supply chains much like a staple product in a retailer’s catalog.

mir-124 medical

"his team identified miR-124 as a key anti-inflammatory drug target for ulcerative"

mir-124 is a tiny piece of genetic material called a microRNA that helps turn genes up or down, especially in brain and nerve cells; think of it as a thermostat that adjusts how much a gene produces. Investors care because changes in mir-124 levels can signal disease, be used as a diagnostic marker, or become a drug target—factors that can influence clinical trial results, regulatory decisions, and the commercial value of therapies.

real-options financial

"developed a real-options financial framework for valuing early-stage biotechnology"

A real option is the right a company has to change a business decision—such as delaying, expanding, contracting, or abandoning a project—without being forced to follow through immediately. Like the option to hold a house while deciding whether to renovate or sell, real options add value by giving management flexibility to respond to new information; investors watch them because they can materially affect a project’s worth and a company’s future cash flows.

AI-generated analysis. Not financial advice.

CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development.

Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmune diseases. Athos has developed AthosOmics.AI, a proprietary AI-driven drug development platform that resulted in the discovery of ATH-063, an AI-derived small molecule currently being evaluated in a Phase 2 clinical trial in ulcerative colitis patients.

He began his academic career at Harvard Medical School as an Assistant Professor of Microbiology & Immunology and later became a tenured Associate Professor of Medicine at the UCLA School of Medicine. At UCLA, he founded and directed the UCLA Center for Systems Biomedicine, funded by the Eli & Edythe Broad Foundation.

Throughout his career, Dr. Iliopoulos has received multiple national and international awards from institutions including the National Institutes of Health (NIH), the American Association for Cancer Research, the Sidney Kimmel Foundation, and the Leona & Harry Helmsley Foundation for identifying novel genes and advancing drug development for autoimmune diseases and cancer. He has published more than 130 peer-reviewed scientific articles in leading biomedical journals, with over 24,000 citations, and has been recognized in Stanford University’s list of the top 2% of scientists worldwide.

Dr. Iliopoulos has developed innovative AI-enabled strategies that have significantly accelerated drug discovery in oncology and autoimmune diseases. His pioneering work at Harvard in drug repositioning demonstrated that metformin, a widely used anti-diabetic drug, possesses anti-cancer properties, leading to multiple cancer clinical trials. At UCLA, his team identified miR-124 as a key anti-inflammatory drug target for ulcerative colitis, contributing to subsequent clinical development programs in inflammatory bowel disease.

He also holds an MBA and a finance certification from UCLA Anderson School of Management and Stanford Graduate School of Business. In addition, he co-authored Biotechnology Valuation & Investing (2nd Edition) and developed a real-options financial framework for valuing early-stage biotechnology products and companies.

Dr. Iliopoulos commented: “I am truly honored to join Cosmos Health’s Advisory Board and to work alongside Greg Siokas, whose visionary leadership and relentless focus on long-term value creation have positioned Cosmos Health as a differentiated and innovation-driven healthcare platform. His ability to combine disciplined execution with bold strategic vision is rare. I look forward to supporting the Company’s biotechnology and AI-driven drug development efforts as it continues to expand its scientific capabilities and build meaningful clinical and commercial impact.”

Greg Siokas, CEO of Cosmos Health, stated: "We are proud to welcome Dr. Iliopoulos to our Advisory Board. His deep expertise in AI-driven drug discovery, translational medicine, and clinical development significantly strengthens our biotechnology platform. As we continue to expand our R&D initiatives and evaluate opportunities in oncology, autoimmune diseases, and other high-value therapeutic areas, his experience at the intersection of science, clinical execution, and biotech strategy will be instrumental in shaping our long-term direction.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

FAQ

Who is Dr. Dimitrios Iliopoulos and why did Cosmos Health (COSM) appoint him to the advisory board on Feb 24, 2026?

Dr. Iliopoulos is an AI-driven drug discovery and clinical-stage biotech expert with academic and CEO experience. According to the company, he will support Cosmos Health’s biotechnology initiatives, focusing on AI drug discovery and clinical therapeutic development across oncology and autoimmune areas.

What relevant AI and clinical accomplishments does Dr. Dimitrios Iliopoulos bring to Cosmos Health (COSM)?

He co-founded an AI biotech with an AI platform that discovered an AI-derived small molecule now in Phase 2. According to the company, his work includes AI-enabled discovery, translational research, and published scientific leadership with significant citations and awards.

How might Dr. Iliopoulos' appointment affect Cosmos Health’s R&D strategy and focus areas (COSM)?

His appointment strengthens Cosmos Health’s focus on AI-driven discovery and clinical-stage programs in oncology and autoimmune diseases. According to the company, he will advise on R&D expansion, translational medicine, and evaluating clinical and commercial opportunities.

Does Dr. Iliopoulos have prior clinical-stage drug development experience relevant to Cosmos Health (COSM)?

Yes. He led programs that advanced an AI-derived small molecule into a Phase 2 ulcerative colitis trial and contributed to other clinical development programs. According to the company, this experience is directly relevant to Cosmos Health’s clinical ambitions.

What credentials and leadership background does Dr. Iliopoulos add to Cosmos Health’s advisory board (COSM)?

He has academic tenure at leading medical schools, founded research centers, holds an MBA and finance certification, and has CEO experience at an AI biotech. According to the company, these credentials support strategic, scientific, and financial guidance for Cosmos Health.

Will Dr. Iliopoulos’ appointment immediately change Cosmos Health’s pipeline or financial guidance (COSM)?

No immediate pipeline changes or financial guidance were announced alongside the appointment. According to the company, his role is advisory to support strategy and R&D evaluation rather than to declare new binding programs or guidance.